2 models fit Healthcare Realty Trust Incorporated Common Stock and they disagree: 0 of 2 land within 15% of the average. The price is above every model.
Two or more of our models back this value.
Large premium(i)
Valued as a REIT (property company): Price to FFO, Dividend discount, and EV/EBITDA comparison.
ACCE opinionHealthcare Realty Trust Incorporated Common Stock (HR)
Fair value (2 models)
$10.86
ACCE price target
$17.50
Rating
Overvalued
Horizon
12 months
Fair value published on 11 Oct 2026, 00:00 CEST; previously $8.65 since 27 Jul 2026, 00:00 CEST.
ACCE price target published on 10 Oct 2026, 00:00 CEST.
Rating published on 20 Oct 2026, 14:06 CEST.
Price used: $17.95 at the close on 23 Oct 2026, 22:00 CEST.
Models: Dividend discount, EV/EBITDA comparison, and Price to FFO.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
65.4% above
-39.5% to fair value
ACCE score
36
out of 100
Analysts
31% buy
13 covering
P/E
0.0x
forward 10.8x
1-year return
-3.9%
Dividend yield
5.35%
Healthcare Realty Trust Incorporated Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Healthcare Realty Trust owns and operates medical office buildings and outpatient healthcare properties, leasing them mainly to health systems and physician groups under long-term tenancies. The structural case rests on demand for outpatient care, which keeps shifting out of hospitals and into lower-cost sites, but that tailwind has not yet shown up in the top line: revenue fell 4.3% over the period, and ROE is slightly negative at -1.9%. The main near-term question is whether occupancy and rent resets stabilise enough to halt that decline, and the market is pricing the stock at a forward P/E of 10.8. A 14.7% operating margin on a 61.9% gross margin shows the portfolio still generates cash at the property level, but a score of 36/100 and no index membership say the rest of the screen has not caught up. It merits a deeper look if you want exposure to medical real estate at a low multiple, with the revenue trend as the key item to test.